Smart Stocks Investing

I thought a good summary of where the Pharmaceutical company has been, and where it is going in the next few years was in order. I focused on GlaxoSmithKline (GSK), Eli Lilly (LLY), Merck (MRK), Bristol-Myers Squibb (BMY) and ‘biotechs’ Genzyme (GENZ), Gilead Sciences (GILD), and others in the past 9 months. But a summary of the industry will serve PSW members well for the future year or so. The market is at a crossroad and I am unsure of which direction the market will go. As was noted on Friday on the laggers/leaders of the past month or so, Telecom and Healthcare were at the bottom of the pile.

For the review of Pharma, generic companies are excluded from all data (Merck KGaA (MKGAY.PK), Mylan (MYL), Teva (TEVA) and Watson (WPI).